SCHEMBL30765472

SCHEMBL30765472

CCCCOC(=O)Cn1c(SC)ncc(NC(C)c2ccc(Oc3ccccc3)cc2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ACACB O00763 9/20 0.42
ACACA Q13085 8/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
GAA P10253 1/20 0.42
LTA4H P09960 1/20 0.37
TSHR P16473 2/20 0.37
IDH1 O75874 2/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.37
APAF1 O14727 1/20 0.37
USP2 O75604 1/20 0.37
RAD52 P43351 1/20 0.37
ALOX15 P16050 1/20 0.37
FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558574 0.73 ELANE (0.46) ACACBACACAIDH1KDM4E
SCHEMBL23474380 0.67 KDM4E (0.41) KDM4E
SCHEMBL6649823 0.63 MEN1 (0.44) MEN1KMT2AL3MBTL1GAATSHR
SCHEMBL23460591 0.62 KDM4E (0.43) KDM4E
SCHEMBL27959245 0.61 ACACA (0.58) KMT2AACACBACACAGAA
SCHEMBL16714725 0.61 ACACA (0.58) KMT2AACACBACACAGAA
Diphenylether SCHEMBL3558137 0.61 LTA4H (0.62) L3MBTL1LTA4HTSHRLMNAMAPK1
SCHEMBL13545912 0.60 LTA4H (1.00) LTA4HLMNAMAPK1
SCHEMBL3996623 0.60 FAAH (0.55) MEN1KMT2AACACBACACAL3MBTL1
SCHEMBL11655422 0.60 LTA4H (0.61) LTA4HTSHRFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed